Literature DB >> 22492469

A quantitative index measured on ⁹⁹mTc GSA SPECT/CT 3D fused images to evaluate severe fibrosis in patients with chronic liver disease.

Morikatsu Yoshida1, Shinya Shiraishi, Fumi Sakaguchi, Daisuke Utsunomiya, Kuniyuki Tashiro, Seiji Tomiguchi, Hirohisa Okabe, Toru Beppu, Hideo Baba, Yasuyuki Yamashita.   

Abstract

PURPOSE: We compared quantitative indices estimated by use of technetium-(99m) galactosyl human serum albumin ((99m)Tc-GSA) single-photon emission computed tomography (SPECT)/computed tomography (CT) fused imaging and hepatic fibrosis in patients with chronic liver disease.
MATERIALS AND METHODS: On the basis of pathological findings we divided 161 patients into non-severe and severe fibrosis groups (n = 81 and n = 80, respectively). We measured 2 indices by (99m)Tc-GSA SPECT/CT fused imaging: liver uptake value (LUV) = [radioactivity (whole liver)/radioactivity (injected)] × 100/body surface area, and functional liver index (FLI) = [radioactivity (hepatocytes)/radioactivity (injected)] × 100/liver volume. We compared these indices with biochemical and histopathological results.
RESULTS: Univariate and multivariate analyses showed that FLI, LUV, LHL15, and prothrombin time were significant independent predictors of severe fibrosis. On the basis of receiver operating characteristics analysis, the areas under curve values of FLI, LUV, LHL15, and prothrombin time for predicting severe fibrosis were 0.83, 0.73, 0.69, and 0.68, respectively. Using an FLI value of 0.053, it was possible to predict severe fibrosis with 65 % sensitivity, 88 % specificity, and 76 % accuracy.
CONCLUSION: Assessment of functional hepatocytes by use of (99m)Tc-GSA SPECT/CT fused images is useful for identifying pathological liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492469     DOI: 10.1007/s11604-012-0072-9

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  32 in total

1.  Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction.

Authors:  Johannes Zeintl; Alexander Hans Vija; Amos Yahil; Joachim Hornegger; Torsten Kuwert
Journal:  J Nucl Med       Date:  2010-05-19       Impact factor: 10.057

2.  Functional mapping of regional liver asialoglycoprotein receptor amount from single blood sample and SPECT.

Authors:  Noriyuki Shuke; Atsutaka Okizaki; Shuichi Kino; Junichi Sato; Yukio Ishikawa; Chunlei Zhao; Seigo Kinuya; Naoto Watanabe; Kunihiko Yokoyama; Tamio Aburano
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

Review 3.  Hepatic vascular bed.

Authors:  C V Greenway; R D Stark
Journal:  Physiol Rev       Date:  1971-01       Impact factor: 37.312

4.  Hepatic lobar differences in progression of chronic liver disease: correlation of asialoglycoprotein scintigraphy and hepatic functional reserve.

Authors:  S Matsuzaki; M Onda; T Tajiri; D Y Kim
Journal:  Hepatology       Date:  1997-04       Impact factor: 17.425

5.  Clinical usefulness of scintigraphy with 99mTc-galactosyl-human serum albumin for prognosis of cirrhosis of the liver.

Authors:  N Sasaki; S Shiomi; Y Iwata; S Nishiguchi; T Kuroki; J Kawabe; H Ochi
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

6.  Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.

Authors:  Youngho Seo; Kenneth H Wong; Mingshan Sun; Benjamin L Franc; Randall A Hawkins; Bruce H Hasegawa
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

7.  Decrease of a hepatic binding protein specific for asialoglycoproteins with accumulation of serum asialoglycoproteins in galactosamine-treated rats.

Authors:  T Sawamura; S Kawasato; Y Shiozaki; Y Sameshima; H Nakada; Y Tashiro
Journal:  Gastroenterology       Date:  1981-09       Impact factor: 22.682

8.  Increased serum levels of hyaluronate in liver disease.

Authors:  A Engström-Laurent; L Lööf; A Nyberg; T Schröder
Journal:  Hepatology       Date:  1985 Jul-Aug       Impact factor: 17.425

9.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

10.  Preoperative evaluation of hepatic functional reserve following hepatectomy by technetium-99m galactosyl human serum albumin liver scintigraphy and computed tomography.

Authors:  A Mitsumori; I Nagaya; S Kimoto; S Akaki; I Togami; Y Takeda; I Joja; Y Hiraki
Journal:  Eur J Nucl Med       Date:  1998-10
View more
  10 in total

1.  Effect of branched-chain amino acid supplementation on functional liver regeneration in patients undergoing portal vein embolization and sequential hepatectomy: a randomized controlled trial.

Authors:  Toru Beppu; Hidetoshi Nitta; Hiromitsu Hayashi; Katsunori Imai; Hirohisa Okabe; Shigeki Nakagawa; Daisuke Hashimoto; Akira Chikamoto; Takatoshi Ishiko; Morikatsu Yoshida; Yasuyuki Yamashita; Hideo Baba
Journal:  J Gastroenterol       Date:  2015-04-08       Impact factor: 7.527

2.  (99m)Tc-GSA SPECT/CT fused images for assessment of hepatic function and hepatectomy planning.

Authors:  Morikatsu Yoshida; Toru Beppu; Shinya Shiraishi; Noriko Tsuda; Fumi Sakamoto; Hirohisa Okabe; Hiromitsu Hayashi; Hideo Baba; Yasuyuki Yamashita
Journal:  Ann Transl Med       Date:  2015-02

3.  Remnant liver volume-based predictors of postoperative liver dysfunction after hepatectomy: analysis of 625 consecutive patients from a single institution.

Authors:  Hirohisa Okabe; Toru Beppu; Akira Chikamoto; Hiromitsu Hayashi; Morikatsu Yoshida; Toshiro Masuda; Katsunori Imai; Kosuke Mima; Shigeki Nakagawa; Hideyuki Kuroki; Hidetoshi Nitta; Takatoshi Ishiko; Daisuke Hashimoto; Yasuyuki Yamashita; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2013-07-17       Impact factor: 3.402

Review 4.  ICG Clearance Test and 99mTc-GSA SPECT/CT Fusion Images.

Authors:  Yuji Iimuro
Journal:  Visc Med       Date:  2017-11-22

5.  Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma.

Authors:  Issam El Naqa; Adam Johansson; Dawn Owen; Kyle Cuneo; Yue Cao; Martha Matuszak; Latifa Bazzi; Theodore S Lawrence; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-02-01       Impact factor: 7.038

6.  Desmin- and vimentin-mediated hepatic stellate cell-targeting radiotracer 99mTc-GlcNAc-PEI for liver fibrosis imaging with SPECT.

Authors:  Deliang Zhang; Rongqiang Zhuang; Zhide Guo; Mengna Gao; Lumei Huang; Linyi You; Pu Zhang; Jindian Li; Xinhui Su; Hua Wu; Xiaoyuan Chen; Xianzhong Zhang
Journal:  Theranostics       Date:  2018-02-02       Impact factor: 11.556

7.  In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT.

Authors:  Niklas Verloh; Ingo Einspieler; Kirsten Utpatel; Karin Menhart; Stefan Brunner; Frank Hofheinz; Jörg van den Hoff; Philipp Wiggermann; Matthias Evert; Christian Stroszczynski; Dirk Hellwig; Jirka Grosse
Journal:  EJNMMI Res       Date:  2018-11-09       Impact factor: 3.138

8.  Three dimensional (3D) CT reconstruction in cancer imaging.

Authors:  V Rangarajan
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

9.  Reliability and advantages of using non-uniform Chang's attenuation correction method using a CT-based attenuation coefficient map in (99m)Tc-GSA SPECT/CT hepatic imaging.

Authors:  Yuya Nakamura; Seiji Tomiguchi; Masayuki Tanaka
Journal:  EJNMMI Phys       Date:  2015-08-14

10.  Heterogeneous liver uptake of Tc-99m-GSA as quantified through SPECT/CT helps to evaluate the degree of liver fibrosis: A retrospective observational study.

Authors:  Kohei Kotani; Joji Kawabe; Shigeaki Higashiyama; Atsushi Yoshida; Etsushi Kawamura; Akihiro Tamori; Susumu Shiomi; Norifumi Kawada
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.